Cue Biopharma (CUE) Return on Capital Employed (2018 - 2025)
Cue Biopharma (CUE) posted Return on Capital Employed of 113.3% for Q4 2025, up 38.69% sequentially from 184.79% in Q3 2025, and up 5396.0% YoY from 2.06% in Q4 2024.
Cue Biopharma (CUE) Return on Capital Employed (2018 - 2025) Analysis & Trends
Cue Biopharma has reported Return on Capital Employed for 8 years, with the latest figure at 113.3% in Q4 2025.
- Quarterly Return on Capital Employed rose 5396.0% year-over-year to 113.3% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 113.3% (up 5396.0% YoY) and the FY2025 annual result came in at 112.0%, up 1311.0% from the prior year.
- Return on Capital Employed improved to 113.3% in Q4 2025 per CUE's latest filing, from 184.79% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 57.51% in Q1 2021 and troughed at 350.8% in Q1 2025.
- A 5-year average of 123.35% and a median of 92.6% in 2023 frame the typical range for Return on Capital Employed.
- The widest YoY moves for Return on Capital Employed: up 5396 bps in 2025, down 22108 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 63.98% in 2021, then dropped by 15 bps to 73.67% in 2022, then plunged by 47 bps to 108.35% in 2023, then tumbled by 54 bps to 167.26% in 2024, then soared by 32 bps to 113.3% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 113.3%, 184.79%, and 322.1% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | -668.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -113.30% |
| Sep 30, 2025 | -184.79% |
| Jun 30, 2025 | -322.10% |
| Mar 31, 2025 | -350.80% |
| Dec 31, 2024 | -167.26% |
| Sep 30, 2024 | -170.65% |
| Jun 30, 2024 | -152.46% |
| Mar 31, 2024 | -129.72% |
| Dec 31, 2023 | -108.35% |
| Sep 30, 2023 | -98.82% |
| Jun 30, 2023 | -86.38% |
| Mar 31, 2023 | -72.06% |
| Dec 31, 2022 | -73.67% |
| Sep 30, 2022 | -65.79% |
| Jun 30, 2022 | -60.75% |
| Mar 31, 2022 | -60.09% |
| Dec 31, 2021 | -63.98% |
| Sep 30, 2021 | -67.93% |
| Jun 30, 2021 | -60.57% |
| Mar 31, 2021 | -57.51% |